Table 1.
Characteristics of the studies included in the systematic review.
| Authors | Year | Country | Journal | Number of patients | Sex | Age | Type of lymphoma | FAPI tracer | SUVmax FAPI | SUVmax FDG |
|---|---|---|---|---|---|---|---|---|---|---|
| Wang et al. | 2025 | China | Clin Nucl Med | 1 | F | 56 | MALT: primary pulmonary MALT | 68Ga-FAPI | 8.1 | 3.7 |
| Hirmas et al. | 2024 | Germany | J Nucl Med | 10 | NR | NR | NR | 68Ga-FAPI | NR | NR |
| Ran et al. | 2024 | China | Clin Nucl Med | 1 | M | 22 | T-cell lymphoma: primary peripheral T-cell lymphoma of the skeletal muscles with brain involvement | 18 F-FAPI-42 | Muscles: 4.9 Brain lesion: 0.9 |
Muscles: 21.3 Brain lesion: 8.9 |
| Liu et al. | 2024 | China | Clin Nucl Med | 1 | F | 44 | T-cell lymphoma: Mycosis fungoides-type cutaneous T-cell lymphoma |
18 F-FAPI-42 | Skin: 11.3 Inguinal lymph nodes: 3.8 |
Skin: 7.7 Inguinal lymph nodes: 5.2 |
| Chen et al. | 2023 | China | J Nucl Med | 186 | 91 M; 95 F | 52 (median) | HL 24 (12.9%) Non-Hodgkin lymphoma 162 (87.1%) DLBCL 80 (43.0%) Primary mediastinal large B-cell lymphoma 4 (2.2%) Mantle cell lymphoma 5 (2.7%) Burkitt lymphoma 2 (1.1%) Lymphoblastic leukemia/lymphoma 6 (3.2%) PTCL 18 (9.7%) Extranodal NK/T-cell lymphoma 6 (3.2%) FL 31 (16.7%) MALT 8 (4.3%) Chronic lymphocytic leukemia/small lymphocytic lymphoma |
68Ga-FAPI | Nodal lesions: HL: 8.6 NHL 7.3 Extranodal lesions: HL: 7.9 NHL: 7.1 |
Nodal lesions: HL: 11.6 NHL: 10.5 Extranodal lesions HL: 10.1 NHL: 11 |
| Lu et al. | 2023 | China | Clin Nucl Med | 1 | M | 73 | DLBLC | 18 F-FAPI | negative | 18.9 |
| Wu et al. | 2022 | China | Diagnostics (Basel) | 1 | M | 82 | T-Cell Lymphoma: Angioimmunoblastic T-Cell Lymphoma |
68Ga-FAPI | 1.6 | 7.6 |
| Jin et al. | 2022 | China | J Nucl Med | 73 (11 HL, 63 NHL) | 36 F; 37 M |
51.6 ± 14.2 | HL, NHL | 68Ga-FAPI | 9.46 | N/A |
| Pang et al. | 2022 | China | Clin Nucl Med | 1 | M | 76 | MALT: primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue |
68Ga-FAPI | 1.56 higher TBR than 18F-FDG (1.6 vs. 0.7). |
2.8 |
| Kou et al. | 2022 | China | Clin Nucl Med | 1 | M | MALT: mucosa-associated lymphoid tissue lymphoma with secondary liver involvement. | Al18F-NOTA-FAPI-04 | Hepatic lesion: 4.9 | Hepatic lesion: no abnormal uptake | |
| Chen et al. | 2022 | China | Clin Nucl Med | 1 | M | 67 | Follicular lymphoma | 68Ga-FAPI-04 | Stomach: 15.1 Lymph nodes: 5.8 |
Stomach: 6 Lymph nodes: 10 |
| Yang et al. | 2022 | China | J Nucl Cardiol | 1 | F | 32 | DLBLC: mediastinal lymphoma | 68Ga-FAPI | 13 | N/A |
| Yang et al. | 2021 | China | Endocrine | 1 | F | 60 | DLBLC: thyroid lymphoma | 68Ga-FAPI | 8.6 | N/A |
| Zhang | 2021 | China | Clin Nucl Med | 1 | F | 67 | DLBLC: primary central nervous system lymphoma | 68Ga-FAPI | CNS lesion: 3.1 | CNS lesion: 9.6 |
| Wang | 2020 | China | Clin Nucl Med | 1 | F | 55 | DLBLC: primary gastric lymphoma | 68Ga-NOTA-FAPI-04 | Stomach: 5 Lymph nodes: 1.4 |
Stomach: 2.9 Lymph nodes: 2 |
NR, not reported; MALT, mucosa-associated lymphoid tissue; DLBLC, diffuse large B-cell lymphoma.